BACKGROUND: TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common treatment-related adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The potential predictive value of neutropenia caused by cytotoxic drugs has been reported in various types of cancer. METHODS: We retrospectively analyzed 95 consecutive patients with metastatic colorectal cancer who received TAS-102 at 2 Japanese institutions between May 2014 and May 2015. To evaluate the association between efficacy and neutropenia, patients were divided into 4 categories according to the grade of neutropenia during the first cycle of TAS-102: Category A (grade 0-1), B (grade 2-4), C (grade 0-2), and D (grade 3-4). RESULTS: Patient characteristics were as follows: median age, 64 years; male, 58%; Eastern Cooperative Oncology Group performance status 0 to 1, 91%; primary site colon, 49%; KRAS exon 2 wild, 57%; and number of metastatic site ≥ 3, 55%. The disease control rate was significantly different between Category A and B (29.2% vs. 52.6%; P = .045) and between Category C and D (30.9% vs. 72.2%; P = .002). In multivariate analysis, Category D remained a significant predictive factor for progression-free survival compared with Category C (4.3 vs. 2.0 months; hazard ratio, 0.45; P = .01). CONCLUSION: Neutropenia caused by TAS-102 during the first cycle was associated with better efficacy. Neutropenia may be a surrogate marker for adequate antitumor doses of TAS-102.
BACKGROUND:TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common treatment-related adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The potential predictive value of neutropenia caused by cytotoxic drugs has been reported in various types of cancer. METHODS: We retrospectively analyzed 95 consecutive patients with metastatic colorectal cancer who received TAS-102 at 2 Japanese institutions between May 2014 and May 2015. To evaluate the association between efficacy and neutropenia, patients were divided into 4 categories according to the grade of neutropenia during the first cycle of TAS-102: Category A (grade 0-1), B (grade 2-4), C (grade 0-2), and D (grade 3-4). RESULTS:Patient characteristics were as follows: median age, 64 years; male, 58%; Eastern Cooperative Oncology Group performance status 0 to 1, 91%; primary site colon, 49%; KRAS exon 2 wild, 57%; and number of metastatic site ≥ 3, 55%. The disease control rate was significantly different between Category A and B (29.2% vs. 52.6%; P = .045) and between Category C and D (30.9% vs. 72.2%; P = .002). In multivariate analysis, Category D remained a significant predictive factor for progression-free survival compared with Category C (4.3 vs. 2.0 months; hazard ratio, 0.45; P = .01). CONCLUSION:Neutropenia caused by TAS-102 during the first cycle was associated with better efficacy. Neutropenia may be a surrogate marker for adequate antitumor doses of TAS-102.
Authors: A Fernandez Montes; F Vazquez Rivera; N Martinez Lago; M Covela Rúa; A Cousillas Castiñeiras; P Gonzalez Villarroel; J de la Cámara Gómez; J C Méndez Méndez; M Salgado Fernández; S Candamio Folgar; M Reboredo López; M Carmona Campos; E Gallardo Martín; M Jorge Fernández; M L Pellón Augusto; L París Bouzas; J García Gómez Journal: Clin Transl Oncol Date: 2019-05-09 Impact factor: 3.405
Authors: Johannes J M Kwakman; G Vink; J H Vestjens; L V Beerepoot; J W de Groot; R L Jansen; F L Opdam; H Boot; G J Creemers; J M van Rooijen; M Los; A J E Vulink; H Schut; E van Meerten; A Baars; P Hamberg; E Kapiteijn; D W Sommeijer; C J A Punt; M Koopman Journal: Int J Clin Oncol Date: 2017-12-04 Impact factor: 3.402
Authors: Vincenzo Sforza; Erika Martinelli; Claudia Cardone; Giulia Martini; Stefania Napolitano; Pietro Paolo Vitiello; Pasquale Vitale; Nicoletta Zanaletti; Alfonso Reginelli; Maurizio Di Bisceglie; Tiziana Pia Latiano; Anna Maria Bochicchio; Fabiana Cecere; Francesco Selvaggi; Fortunato Ciardiello; Teresa Troiani Journal: ESMO Open Date: 2017-09-21
Authors: Axel Grothey; Takayuki Yoshino; Gyorgy Bodoky; Tudor Ciuleanu; Rocio Garcia-Carbonero; Pilar García-Alfonso; Eric Van Cutsem; Kei Muro; Daniel S Mytelka; Li Li; Olga Lipkovich; Yanzhi Hsu; Andreas Sashegyi; David Ferry; Federico Nasroulah; Josep Tabernero Journal: ESMO Open Date: 2018-04-24